CYCN: Cyclerion Total Debt to Capital

Cyclerion Therapeutics (CYCN) focuses on treating CNS pathologies by studying soluble guanylate cyclase, a pursuit highly valued within the scientific community. The business model relies on external contractors to conduct testing, thereby minimizing capital expenditures. However, uncertainty surrounding licenses and restructuring creates risks of asset impairment. The price action for the company available on the GURU.Markets chart confirms these risks, while the individual debt-to-equity ratio stands at 0.00.

For Cyclerion Therapeutics (CYCN), the debt-to-equity ratio, recorded at 0.00, reflects the effectiveness of the current austerity policy. This metric is calculated as the ratio of total liabilities to equity, determining the business's degree of dependence on external loans and the overall financial stability of the asset amid an unstable long-term development strategy.